ABSTRACT
Objective To determine the relative risk of drug-induced Long QT Syndrome (LQTS) associated with SARS-CoV-2 (COVID-19) proposed repurposed drugs compared to well-known torsadogenic compounds.
Setting Computer calculations and simulations were performed using primary pharmacokinetic and pharmacodynamic data for each proposed drug. Seven different LQTS indices were calculated and compared. The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events.
Interventions A thorough literature search was performed to gather information on the pharmacological properties of six drugs (azithromycin, chloroquine, favipiravir, hydroxychloroquine, lopinavir/ritonavir, and remdesivir) repurposed to treat COVID-19. Researchers emphasized the affinity of these drugs to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether-a-go-go gene (hERG), their propensity to prolong cardiac repolarization (QT interval), and cause torsade de pointes (TdP). The risk of drug-induced LQTS for these drugs was quantified by comparing six indices that assess such risk.
Primary and secondary outcome measures Level of risk estimated for the six COVID-19 drugs being proposed compared to 23 torsadogenic drugs. Number of proarrhythmic adverse events identified for these drugs in the FAERS.
Results Estimators of LQTS risk levels indicated a very high or high risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the six repurposed drugs and 23 torsadogenic compounds.
Conclusion The risk-benefit assessment for the use of repurposed drugs to treat COVID-19 is complicated since benefits are currently anticipated, not proven. Mandatory monitoring of the QT interval shall be performed, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients prescribed these drugs.
Strengths and limitations of this study
Our study systematically explores current research and validated indices related to drug-induced LQTS, in addition to consider the various mechanisms of action for these drugs to induce LQTS.
To our knowledge, this is the first comparison of risk for a prolonged QT interval and torsade de pointes in the use of hydroxychloroquine, chloroquine, remdesivir or lopinavir/ritonavir to 23 well-known torsadogenic drugs.
The comprehensive analysis of arrhythmogenic events reported for COVID-19 drugs and torsadogenic compounds from the FAERS.
Our conclusions are limited by the limited availability of basic pharmacokinetic and pharmacodynamic parameters and clinical data for some of the newer COVID-19 drugs.
Competing Interest Statement
Veronique Michaud, Pamela Dow, Sweilem Al Rihani, Malavika Deodhar, Meghan Arwood, and Jacques Turgeon are all employees of Tabula Rasa HealthCare. Jacques Turgeon and Veronique Michaud are stock holders of Tabula Rasa HealthCare. Jacques Turgeon and Veronique Michaud have patents broadly related to the content of this paper. Veronique Michaud and Jacques Turgeon are faculty members at the Universite de Montreal. Brian Cicali is a previous employee of Tabula Rasa HealthCare, and is paid independently by TRHC for work outside of this paper.
Funding Statement
This research was made possible by funding from Tabula Rasa HealthCare.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
vmichaud{at}trhc.com, pdow{at}trhc.com, srihani{at}trhc.com, mdeodhar{at}trhc.com, marwood{at}trhc.com, bcicali{at}ufl.edu, jturgeon{at}trhc.com
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.
